BEAM
Beam Therapeutics Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Neutral
-18/100
Last price
25.25
▼ 0.42 (1.64%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
25.55
Prev close
25.67
Day high
26.94
Day low
24.87
Volume
2.52M
Market cap
$2.61B
P/E (TTM)
—
52W range
20.23 – 38.26
Day trading desk
Gap from prior close
-0.47%
Prior close 25.67
VWAP
25.38
-0.52% from price
Relative volume
2.30×
Unusually busy
Session range
9.17%
24.87 – 27.15
Position in range
17%
Near session low
ATR (14D)
1.42
5.64% of price
Prior day high
26.04
PDH
Prior day low
23.83
PDL
Bid / ask spread
—
Quote not published
Session volume
4.45M
Avg 1.93M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+2.90%
+0.9%
1M
-14.94%
-16.1%
3M
-31.59%
-36.1%
6M
+3.02%
-15.2%
YTD
-8.98%
-23.2%
1Y
-2.02%
-18.4%
3Y
+4.91%
-77.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on BEAM open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
-266.39K
Net selling
Buy transactions
2
85.50K shares
Sell transactions
4
351.90K shares
Net transactions
+6
Buys less sells
Sell : buy shares
4.1 : 1
Mixed
Insider-held shares
1.20M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jul 27, 26 | SIMON AMY Officer |
SELL | 16.67K | $429.04K | Direct |
| Jun 30, 26 | EVANS JOHN M. Chief Executive Officer |
CONVERSION | 50.00K | $44.78K | Direct |
| Jun 30, 26 | EVANS JOHN M. Chief Executive Officer |
SELL | 50.00K | $1.75M | Direct |
| Jun 30, 26 | SIMON AMY Officer |
SELL | 373 | $12.95K | Direct |
| Jun 26, 26 | FMR, L.L.C. Beneficial Owner of more than 10% of a Class of Security |
SELL | 284.86K | $10.04M | Indirect |
| Jun 17, 26 | CIARAMELLA GIUSEPPE President |
CONVERSION | 35.51K | $34.23K | Direct |
| Apr 1, 26 | CIARAMELLA GIUSEPPE President |
SELL | 11.81K | $290.29K | Direct |
| Apr 1, 26 | EVANS JOHN M. Chief Executive Officer |
SELL | 30.08K | $739.32K | Direct |
| Apr 1, 26 | BELLON CHRISTINE Officer |
SELL | 5.96K | $146.40K | Direct |
| Apr 1, 26 | SIMON AMY Officer |
SELL | 6.70K | $164.69K | Direct |
| Apr 1, 26 | CAVANAGH BETHANY J Officer and Treasurer |
SELL | 3.24K | $79.69K | Direct |
| Mar 31, 26 | CIARAMELLA GIUSEPPE President |
STOCK | 40.00K | $0 | Direct |
| Mar 31, 26 | EVANS JOHN M. Chief Executive Officer |
STOCK | 90.00K | $0 | Direct |
| Mar 31, 26 | EMANY SRAVAN KUMAR Chief Financial Officer |
STOCK | 31.75K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BELLON CHRISTINE |
Officer | 109.71K | Sale |
CAVANAGH BETHANY J |
Officer and Treasurer | 51.17K | Sale |
CIARAMELLA GIUSEPPE |
President | 253.91K | Conversion of Exercise of derivative security |
EMANY SRAVAN KUMAR |
Chief Financial Officer | 105.46K | Stock Award(Grant) |
EVANS JOHN M. |
Chief Executive Officer | 1.15M | Conversion of Exercise of derivative security |
FMR, L.L.C. |
Beneficial Owner of more than 10% of a Class of Security | — | Sale |
SIMON AMY |
Officer | 85.70K | Sale |
Fundamentals
Market cap$2.61B
Enterprise value$1.62B
Revenue (TTM)$156.04M
Gross profit$-252.63M
EBITDA$-355.78M
Net income$-86.52M
EPS (TTM)$-0.68
Free cash flow$-241.84M
Total cash$1.15B
Total debt$247.36M
Book value / share$10.69
Shares outstanding103.29M
Float88.33M
Short % of float38.75%
Dividend yield0.00%
Beta (5Y)2.20
Valuation & profitability ratios
Trailing P/E—
Forward P/E-5.32
PEG ratio—
Price / sales—
Price / book2.36
EV / revenue10.35
EV / EBITDA-4.54
Gross margin-161.91%
Operating margin-25827.14%
Profit margin-55.45%
Return on equity-8.18%
Return on assets-17.01%
Debt / equity23.17
Current ratio14.57
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $139.74M | $63.52M | $377.71M | $60.92M | +120.0% |
| Operating revenue | $139.74M | $63.52M | $377.71M | $60.92M | +120.0% |
| Research & development | $409.62M | $367.56M | $437.38M | $311.59M | +11.4% |
| Selling, general & admin | $113.82M | $111.53M | $116.81M | $87.81M | +2.1% |
| Total operating expense | $523.44M | $479.09M | $554.19M | $399.40M | +9.3% |
| Operating income | -$383.69M | -$415.57M | -$176.49M | -$338.48M | +7.7% |
| Net interest income | $43.73M | $49.09M | $46.68M | $15.30M | -10.9% |
| Pre-tax income | -$79.99M | -$376.70M | -$131.16M | -$260.18M | +78.8% |
| Tax provision | $0 | $39.00K | $1.37M | $3.41M | -100.0% |
| Net income | -$79.99M | -$376.74M | -$132.53M | -$289.09M | +78.8% |
| Net income to common | -$79.99M | -$376.74M | -$132.53M | -$289.09M | +78.8% |
| Basic EPS | -0.81 | -4.58 | -1.72 | -4.13 | +82.3% |
| Diluted EPS | -0.81 | -4.58 | -1.72 | -4.13 | +82.3% |
| EBIT | -$383.69M | -$415.57M | -$176.49M | -$338.48M | +7.7% |
| EBITDA | -$361.40M | -$393.64M | -$156.47M | -$315.90M | +8.2% |
| Basic shares | 98.91M | 82.31M | 77.15M | 70.02M | +20.2% |
| Diluted shares | 98.91M | 82.31M | 77.15M | 70.02M | +20.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $294.94M | $281.97M | $435.89M | $232.77M | — | +4.6% |
| Cash & short-term investments | $1.25B | $850.74M | $1.19B | $1.08B | — | +46.4% |
| Accounts receivable | — | — | — | $0 | $300.00M | — |
| Total current assets | $1.27B | $878.15M | $1.21B | $1.09B | — | +44.5% |
| Property, plant & equipment | $205.18M | $216.28M | $237.81M | $234.13M | — | -5.1% |
| Total assets | $1.48B | $1.10B | $1.46B | $1.34B | — | +34.2% |
| Total current liabilities | $96.94M | $182.07M | $205.56M | $223.59M | — | -46.8% |
| Current debt | — | — | — | — | $2.29M | — |
| Long-term debt | — | — | — | — | $3.01M | — |
| Total debt | $154.12M | $161.43M | $172.69M | $179.00M | — | -4.5% |
| Total liabilities | $242.82M | $370.28M | $478.38M | $608.24M | — | -34.4% |
| Retained earnings | -$1.64B | -$1.57B | -$1.19B | -$1.06B | — | -4.8% |
| Shareholder equity | $1.24B | $733.54M | $981.33M | $733.47M | — | +68.8% |
| Working capital | $1.17B | $696.08M | $1.01B | $869.30M | — | +68.3% |
| Net tangible assets | $1.24B | $733.54M | $981.33M | $733.47M | — | +68.8% |
| Shares issued | 101.75M | 83.63M | 81.63M | 71.28M | — | +21.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$79.99M | -$376.74M | -$132.53M | -$289.09M | +78.8% |
| Depreciation & amortisation | $22.29M | $21.93M | $20.01M | $22.58M | +1.7% |
| Stock-based compensation | $94.24M | $120.66M | $98.65M | $84.32M | -21.9% |
| Change in working capital | -$131.02M | -$110.22M | -$116.45M | $251.63M | -18.9% |
| Operating cash flow | -$345.10M | -$347.25M | -$149.19M | $22.53M | +0.6% |
| Capital expenditure | -$14.95M | -$8.95M | -$33.73M | -$48.95M | -67.1% |
| Investing cash flow | -$121.44M | $185.01M | $71.84M | -$461.34M | -165.6% |
| Financing cash flow | $478.05M | $7.74M | $276.45M | $111.59M | +6,079.5% |
| Free cash flow | -$360.05M | -$356.19M | -$182.93M | -$26.42M | -1.1% |
| End cash position | $301.62M | $290.11M | $444.61M | $245.52M | +4.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $490.00K | $31.74M | $114.11M | $9.70M | $8.47M | -98.5% |
| Operating revenue | $490.00K | $31.74M | $114.11M | $9.70M | $8.47M | -98.5% |
| Research & development | $95.10M | $104.52M | $99.28M | $109.77M | $101.76M | -9.0% |
| Selling, general & admin | $31.95M | $34.43M | $32.28M | $26.74M | $26.86M | -7.2% |
| Total operating expense | $127.04M | $138.95M | $131.55M | $136.51M | $128.62M | -8.6% |
| Operating income | -$126.55M | -$107.22M | -$17.45M | -$126.81M | -$120.15M | -18.0% |
| Net interest income | $7.49M | $9.87M | $10.64M | $10.90M | $12.33M | -24.1% |
| Pre-tax income | -$123.13M | -$94.32M | $244.30M | -$112.73M | -$102.14M | -30.6% |
| Tax provision | -$455.00K | — | $0 | $0 | $0 | — |
| Net income | -$122.68M | -$94.32M | $244.30M | -$112.73M | -$102.14M | -30.1% |
| Net income to common | -$122.68M | -$94.32M | $244.30M | -$112.73M | -$102.14M | -30.1% |
| Basic EPS | -1.18 | -0.91 | 2.37 | -1.10 | -1.00 | -29.7% |
| Diluted EPS | -1.18 | -0.91 | 2.33 | -1.10 | -1.00 | -29.7% |
| EBIT | -$126.55M | -$107.22M | -$17.45M | -$126.81M | -$120.15M | -18.0% |
| EBITDA | -$121.14M | -$101.61M | -$11.78M | -$121.25M | -$114.61M | -19.2% |
| Basic shares | 104.33M | 103.26M | 102.88M | 102.57M | 102.00M | +1.0% |
| Diluted shares | 104.33M | 103.26M | 104.93M | 102.57M | 102.00M | +1.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $219.82M | $288.29M | $294.94M | $267.96M | $282.13M | -23.7% |
| Cash & short-term investments | $1.15B | $1.21B | $1.25B | $1.07B | $1.15B | -4.8% |
| Total current assets | $1.18B | $1.27B | $1.27B | $1.10B | $1.18B | -7.0% |
| Property, plant & equipment | $193.19M | $199.40M | $205.18M | $205.28M | $208.39M | -3.1% |
| Total assets | $1.39B | $1.48B | $1.48B | $1.31B | $1.39B | -6.4% |
| Total current liabilities | $80.88M | $74.56M | $96.94M | $182.56M | $174.13M | +8.5% |
| Long-term debt | $100.26M | $100.19M | — | — | — | +0.1% |
| Total debt | $247.36M | $250.82M | $154.12M | $151.42M | $154.80M | -1.4% |
| Total liabilities | $318.91M | $316.36M | $242.82M | $345.08M | $344.34M | +0.8% |
| Retained earnings | -$1.86B | -$1.74B | -$1.64B | -$1.89B | -$1.78B | -7.1% |
| Shareholder equity | $1.07B | $1.16B | $1.24B | $966.00M | $1.05B | -8.3% |
| Working capital | $1.10B | $1.19B | $1.17B | $915.99M | $1.00B | -7.9% |
| Net tangible assets | $1.07B | $1.16B | $1.24B | $966.00M | $1.05B | -8.3% |
| Shares issued | 103.26M | 102.74M | 101.75M | 101.36M | 100.76M | +0.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$122.68M | -$94.32M | $244.30M | -$113.82M | -$102.14M | -30.1% |
| Depreciation & amortisation | $5.41M | $5.61M | $5.67M | $5.56M | $5.54M | -3.5% |
| Stock-based compensation | $19.28M | $19.04M | $20.45M | $22.75M | $24.37M | +1.2% |
| Change in working capital | $28.22M | -$55.62M | -$101.86M | -$7.12M | $3.44M | +150.7% |
| Operating cash flow | -$66.10M | -$128.51M | -$83.29M | -$81.48M | -$76.45M | +48.6% |
| Capital expenditure | -$2.41M | -$2.23M | -$3.73M | -$5.01M | -$3.14M | -8.2% |
| Investing cash flow | -$9.88M | $25.27M | $108.41M | $65.66M | -$170.41M | -139.1% |
| Financing cash flow | $7.52M | $96.61M | $1.89M | $1.68M | $1.11M | -92.2% |
| Free cash flow | -$68.51M | -$130.75M | -$87.02M | -$86.49M | -$79.59M | +47.6% |
| End cash position | $226.54M | $294.98M | $301.62M | $274.62M | $288.76M | -23.2% |
Options analytics
Put / call volume
1.53
Put-heavy session
Put / call open interest
0.59
Positioning, not flow
Max pain
26.00
+3.1% from spot
ATM implied vol
59.2%
Nearest strike to spot
Skew (10% OTM)
-4.4%
Calls bid over puts
Call volume
322
Contracts, this expiry
Put volume
494
Contracts, this expiry
Heaviest call OI
30.00
1.06K contracts
Heaviest put OI
23.00
413 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -1.13 | -1.18 | -4.8% |
| Mar 2026 | -1.01 | -0.91 | +10.1% |
| Dec 2025 | -1.12 | 2.33 | +309.0% |
| Sep 2025 | -1.01 | -1.10 | -8.9% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -1.17 | 13 | $9.96M | +2.7% |
| Next quarter | -1.19 | 13 | $11.57M | -89.9% |
| Current year | -4.45 | 14 | $48.57M | -65.2% |
| Next year | -4.74 | 12 | $62.75M | +29.2% |
Analyst targets & ownership
Mean target$52.15
High target$80.00
Low target$26.00
Implied upside106.55%
Analyst count13
ConsensusSTRONG BUY
Strong buy / Buy1 / 12
Hold2
Sell / Strong sell0 / 0
Held by insiders1.20%
Held by institutions107.92%
Institutions holding398
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
24.63
+2.52% from price
SMA 20
24.55
+2.75% from price
SMA 50
26.59
-5.11% from price
SMA 100
28.72
-12.09% from price
SMA 200
28.47
-11.38% from price
EMA 12
24.91
+1.36% from price
EMA 26
25.52
-1.07% from price
EMA 50
26.55
-4.89% from price
RSI (14)
47.8
Neutral
MACD (12,26,9)
-0.61
Hist 0.21
ATR (14)
1.42
5.65% of price
Realised vol 30D
57.7%
Annualised
Bollinger upper
25.92
20, 2σ
Bollinger lower
23.19
20, 2σ
50 / 200 cross
Death
26.59 vs 28.47
Trend bias
Below 200
-11.38%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
2.11
More volatile than market
Correlation to SPY
0.37
Loosely linked
Realised vol 30D
57.7%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-39.1%
Peak to trough
Max drawdown 5Y
-85.3%
Peak to trough
ATR 14
1.42
5.65% of price
Beta (reported)
2.20
5Y monthly, from filing
Short interest
Shares short
25.88M
Prior 24.37M
Change vs prior
+6.2%
Shorts adding
% of float
38.75%
Heavily shorted
% of shares out
25.06%
Against total outstanding
Days to cover
13.5
Crowded exit
Float
88.33M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 9, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Aug 25, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jul 8, 26 | B of A Securities | MAINTAINED | Buy | Buy |
| Jul 7, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 13, 26 | Bernstein | MAINTAINED | Outperform | Outperform |
| Mar 26, 26 | Citigroup | MAINTAINED | Buy | Buy |
| Feb 25, 26 | RBC Capital | MAINTAINED | Sector Perform | Sector Perform |
| Feb 25, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Feb 20, 26 | Canaccord Genuity | INITIATED | — | Buy |
| Jan 21, 26 | Bernstein | MAINTAINED | Outperform | Outperform |
| Jan 7, 26 | UBS | INITIATED | — | Neutral |
| Nov 24, 25 | Evercore ISI Group | INITIATED | — | Outperform |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-04
Corporate Changes & Voting Matters
8-K · 2026-06-08
Periodic Financial Reports
10-Q · 2026-05-07
Proxy Statements
DEFA14A · 2026-04-17
Corporate Changes & Voting Matters
8-K · 2026-03-05
Offering Registrations
S-8 · 2026-02-24
Corporate Changes & Voting Matters
8-K · 2026-02-12
Corporate Changes & Voting Matters
8-K · 2026-02-05
Headlines
Will IP Theft Allegations Against YolTech and Serapha Bio Change Beam Therapeutics' (BEAM) Narrative
Simply Wall St. · 6d ago
Beam sues 2 biotechs, alleging theft of base editing trade secrets
BioPharma Dive · 7d ago
Temporary Weakness in Intellia Stock Seems Like a Buying Opportunity
Barchart · 8d ago
As Claude Enters the Gene-Editing Arena, There’s Still a Long-Term Case for BEAM Stock
Barchart · 8d ago
Cathie Wood Makes $64 Million Bet on Two Stocks
GuruFocus.com · 8d ago
Anthropic AI Discovery Gene-Editing Stocks Falling
GuruFocus.com · 13d ago
Beam Therapeutics (BEAM) Stock Could Trade At A Premium As Gene Editing Interest Grows
Simply Wall St. · 13d ago
CRISPR Therapeutics Traded Sideways and Down for 12 Months: One Wall Street Pro Expects 85% Gains Soon
24/7 Wall St. · 14d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.